TY - JOUR
T1 - Stereotactic body radiotherapy for kidney cancer
T2 - a 10-year experience from a single institute
AU - Yamamoto, Takaya
AU - Kawasaki, Yoshihide
AU - Umezawa, Rei
AU - Kadoya, Noriyuki
AU - Matsushita, Haruo
AU - Takeda, Kazuya
AU - Ishikawa, Yojiro
AU - Takahashi, Noriyoshi
AU - Suzuki, Yu
AU - Takeda, Ken
AU - Kawabata, Kousei
AU - Ito, Akihiro
AU - Jingu, Keiichi
N1 - Publisher Copyright:
© 2021 The Author(s) 2020. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.
PY - 2021/5/1
Y1 - 2021/5/1
N2 - The purpose of this retrospective study was to investigate survival outcomes and irradiated tumor control (local control [LC]) and locoregional control (LRC) after stereotactic body radiotherapy (SBRT) for T1 or recurrent T1 (rT1) kidney cancer. Twenty-nine nonconsecutive patients with 30 tumors were included. SBRT doses of 70 Gy, 60 Gy or 50 Gy in 10 fractions were prescribed with a linear accelerator using daily image guidance. The Kaplan-Meier method was used to estimate time-to-event outcomes, and the log-rank test was used to compare survival curves between groups divided by each possible factor. The median follow-up periods for all patients and survivors were 57 months and 69.6 months, respectively. The five-year LC rate, LRC rate, progression-free survival (PFS) rate, disease-specific survival (DSS) rate and overall survival (OS) rate were 94%, 88%, 50%, 96% and 68%, respectively. No significant factor was related to OS and PFS. Three of 24 non-hemodialysis (HD) patients had new-onset-HD because of the progression of underlying kidney disease. Grade 3 or higher toxicities from SBRT did not occur. In conclusion, SBRT for kidney cancer provided a high rate of LC, LRC and DSS with minimal toxicities, but patient selection and indication for SBRT should be done carefully considering the relatively low OS rate.
AB - The purpose of this retrospective study was to investigate survival outcomes and irradiated tumor control (local control [LC]) and locoregional control (LRC) after stereotactic body radiotherapy (SBRT) for T1 or recurrent T1 (rT1) kidney cancer. Twenty-nine nonconsecutive patients with 30 tumors were included. SBRT doses of 70 Gy, 60 Gy or 50 Gy in 10 fractions were prescribed with a linear accelerator using daily image guidance. The Kaplan-Meier method was used to estimate time-to-event outcomes, and the log-rank test was used to compare survival curves between groups divided by each possible factor. The median follow-up periods for all patients and survivors were 57 months and 69.6 months, respectively. The five-year LC rate, LRC rate, progression-free survival (PFS) rate, disease-specific survival (DSS) rate and overall survival (OS) rate were 94%, 88%, 50%, 96% and 68%, respectively. No significant factor was related to OS and PFS. Three of 24 non-hemodialysis (HD) patients had new-onset-HD because of the progression of underlying kidney disease. Grade 3 or higher toxicities from SBRT did not occur. In conclusion, SBRT for kidney cancer provided a high rate of LC, LRC and DSS with minimal toxicities, but patient selection and indication for SBRT should be done carefully considering the relatively low OS rate.
KW - kidney cancer
KW - local control (LC)
KW - renal cell carcinoma
KW - stereotactic body radiotherapy (SBRT)
UR - http://www.scopus.com/inward/record.url?scp=85106552805&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106552805&partnerID=8YFLogxK
U2 - 10.1093/jrr/rrab031
DO - 10.1093/jrr/rrab031
M3 - Article
C2 - 33866363
AN - SCOPUS:85106552805
SN - 0449-3060
VL - 62
SP - 533
EP - 539
JO - Journal of Radiation Research
JF - Journal of Radiation Research
IS - 3
ER -
